Atopaxar|751475-53-3|(E5555; ER-172594-00)-陌孚医药/Medlife

您当前的位置：

Atopaxar (Synonyms: E5555; ER-172594-00)

目录号: PL10691 纯度: ≥98%

CAS No. :751475-53-3

商品编号	规格	价格	会员价
PL10691-5mg	5mg	¥2225.45	请登录
PL10691-10mg	10mg	¥3832.73	请登录
PL10691-25mg	25mg	¥8407.27	请登录
PL10691-50mg	50mg	¥13352.73	请登录
PL10691-100mg	100mg	¥22254.55	请登录
PL10691-200mg	200mg	询价	询价
PL10691-500mg	500mg	询价	询价
PL10691-10mM*1mLinDMSO	10mM*1mLinDMSO	¥2448.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Atopaxar
中文别名	2-(5,6-二乙氧基-7-氟-1,3-二氢-1-亚氨基-2H-异吲哚-2-基)-1-[3-(1,1-二甲基乙基)-4-甲氧基-5-(4-吗啉)苯基]乙酮;2-(5,6-二乙氧基-7-氟-1,3-二氢-1-亚氨基-2H-异吲哚-2-基)-1-[3-叔丁基-4-甲氧基-5-(4-吗啉基)苯基]乙酮
英文名称	Atopaxar
英文别名	Atopaxar;1-(3-tert-butyl-4-methoxy-5-morpholin-4-ylphenyl)-2-(5,6-diethoxy-4-fluoro-3-imino-1H-isoindol-2-yl)ethanone;2-(5,6-diethoxy-7-fluoro-1,3-dihydro-1-imino-2H-isoindol-2-yl)-1-[3-(1,1-dimethylethyl)-4-methoxy-5-(4-morpholinyl)phenyl]Ethanone
Cas No.	751475-53-3
分子式	C₂₉H₃₈N₃O₅F^.HBr
分子量	608.54
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情

Atopaxar (E5555) 是一种高效、有口服活性活性的，选择性的，可逆的凝血酶受体蛋白酶激活受体-1 (PAR-1) 拮抗剂。Atopaxar 是一种抗血小板剂，能干扰血小板信号。Atopaxar 可用于动脉粥样硬化血栓性疾病的研究。

生物活性

Atopaxar (E5555) is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist. Atopaxar, an antiplatelet agent, interferes with platelet signaling. Atopaxar can be used for the research of atherothrombotic disease.

性状

Solid

IC50 & Target[1][2]

PAR-1

体外研究(In Vitro)

Atopaxar (0.0001-10 μM; 1h) inhibits haTRAP (high-affinity thrombin receptor activating peptide) binding to PAR-1 on human platelet membranes in a concentration-dependent manner, with an IC50 of 0.019 μM.
Atopaxar inhibits human platelet aggregation induced by thrombin or TRAP in a concentration-dependent manner.
Atopaxar does not inhibit PRP (platelet-rich plasma) aggregation induced by ADP, U46619, collagen, and PAR-4ap, up to a concentration of 20 μM.
has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Atopaxar (30-100 mg/kg; p.o.) causes a dose-dependent prolongation of the time to occlusion of the femoral artery in photochemically-induced thrombosis (PIT) guinea pigs model.
Atopaxar does not prolong bleeding time in guinea pigs at the highest tested dosage of 1000 mg/kg.
has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Chris Dockendorff, et al. Discovery of 1,3-Diaminobenzenes as Selective Inhibitors of Platelet Activation at the PAR1 Receptor. ACS Med Chem Lett. 2012 Mar 8; 3(3): 232–237.
[2]. Motoji Kogushi, et al. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs. Eur J Pharmacol. 2011 Apr 25;657(1-3):131-7.

溶解度数据	In Vitro: DMSO : 50 mg/mL (94.76 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation